Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neuroscience Letters

• Publication date

  2004-05-06

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/J.NEULET.2003.12.005PMID 15135910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of a plus-maze to measure anxiety in the mouse

  2004cited by this paper
• Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults

  2003cited by this paper
• NAP accelerates the performance of normal rats in the water maze

  2002cited by this paper
• A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury

  2002cited by this paper
• The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders.

  2002cited by this paper
• NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death

  2002cited by this paper
• Role of the PLC‐related, catalytically inactive protein p130 in GABAA receptor function

  2002cited by this paper
• Factors controlling measures of anxiety and responses to novelty in the mouse.

  2001cited by this paper
• Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.

  2001cited by this paper
• Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein*

  2001cited by this paper
• A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.

  2001cited by this paper
• Measuring normal and pathological anxiety-like behaviour in mice: a review.

  2001cited by this paper
• Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.

  2000cited by this paper
• Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

  2000cited by this paper
• Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide

  1999cited by this paper
• Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests.

  1999cited by this paper
• A review of the validity and variability of the elevated plus-maze as an animal model of anxiety.

  1996cited by this paper
• Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice.

  1995cited by this paper
• DSM-IV: Diagnostic and Statistical Manual of Mental Disorders

  1994cited by this paper
• Developments of a water-maze procedure for studying spatial learning in the rat.

  1984cited by this paper
• An automatic device for forced wakefulness in dogs.

  1979cited by this paper

• Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity.

  2025cites this paper
• Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease

  2024cites this paper
• Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development

  2022cites this paper
• SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism

  2022cites this paper
• Direct Delivery of ANA-TA9, a Peptide Capable of Aβ Hydrolysis, to the Brain by Intranasal Administration

  2021cites this paper
• Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): Autism, schizophrenia, and Alzheimer’s disease

  2020cites this paper
• Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting

  2020cites this paper
• Age and Sex-Dependent ADNP Regulation of Muscle Gene Expression Is Correlated with Motor Behavior: Possible Feedback Mechanism with PACAP

  2020cites this paper
• Sedative and Anxiolytic Activities of Opuntia ficus indica (L.) Mill.: An Experimental Assessment in Mice

  2020cites this paper
• VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects

  2020cites this paper
• Functional effects of synthetic cannabinoids versus Δ9‐THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression

  2019cites this paper
• Cellular and animal models of skin alterations in the autism-related ADNP syndrome

  2019cites this paper
• The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse

  2019cites this paper
• Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

  2019cites this paper
• Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice

  2018cites this paper
• Evaluation of intranasal delivery route of drug administration for brain targeting.

  2018cites this paper
• Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome

  2018cites this paper
• Nose-to-brain peptide delivery - The potential of nanotechnology.

  2017cites this paper
• Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats.

  2017cites this paper
• Neuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP

  2017cites this paper
• Novel GLP‐1R/GIPR co‐agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

  2017cites this paper
• Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy

  2016cites this paper
• Inhalation of growth factors and apo-transferrin to protect and repair the hypoxic-ischemic brain.

  2016cites this paper
• Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory

  2016cites this paper
• eview nhalation of growth factors and apo-transferrin to protect and repair he hypoxic-ischemic brain

  2016cites this paper
• Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model

  2015cites this paper
• Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies

  2015cites this paper
• NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions

  2015cites this paper
• Pharmacological approaches for Alzheimer’s disease: neurotransmitter as drug targets

  2015cites this paper
• New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia

  2014cites this paper
• Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein

  2014influential citation
• Brain Delivery of NAP with PEG-PLGA Nanoparticles Modified with Phage Display Peptides

  2013cites this paper
• Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice.

  2013cites this paper
• NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

  2013cites this paper
• Anxiolytic Properties of New Chemical Entity, 5TIO1

  2013cites this paper
• Nanotechnology for CNS delivery of bio-therapeutic agents

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Hyperbaric oxygen-induced seizures cause a transient decrement in cognitive function.

  2013cites this paper
• Intranasal administration of oxytocin: Behavioral and clinical effects, a review

  2013cites this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cites this paper
• Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice

  2012cites this paper
• Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

  2012cites this paper
• Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects.

  2012cites this paper
• NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia.

  2011cites this paper
• A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

  2011cites this paper
• Ameliorative effect of NAP on laser‐induced retinal damage

  2011cites this paper
• The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI)

  2011cites this paper
• Behavioral consequences of minimal traumatic brain injury in mice.

  2011cites this paper
• Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.

  2011cites this paper
• Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain.

  2011cites this paper
• Effects of central neuropeptides on social preference and social recognition in male rats

  2011cites this paper
• Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice

  2011cites this paper
• Intranasal delivery of neuropeptides.

  2011cites this paper
• Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

  2011cites this paper
• NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.

  2010cites this paper
• The Influence of Alcohol on Behavioral Recovery after mTBI in Mice

  2010cites this paper
• Molecular Therapy for Mucopolysaccharidosis Type I

  2010cites this paper
• Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.

  2010cites this paper
• Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimer’s Disease

  2010cites this paper
• Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles

  2009cites this paper
• NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

  2009cites this paper
• Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

  2009cites this paper
• Intranasal Targeting of Neuropeptides to the Central Nervous System: Evaluation of Pharmacokinetics, Pharmacodynamics, and a Novel Vasoconstrictor Formulation

  2009cites this paper
• A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

  2008influential citation
• Parkinson’s and Alzheimer’s diseases

  2007cites this paper
• From Concept to Potential Therapeutics: Neuroprotective Peptides

  2007cites this paper
• Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry

  2007cites this paper
• Neuropeptides 2003

  2007cites this paper
• Activity-dependent neuroprotective protein: from gene to drug candidate.

  2007cites this paper
• NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.

  2007cites this paper
• Looking for novel ways to treat the hallmarks of Alzheimer's disease

  2007cites this paper
• Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model

  2007cites this paper
• Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS

  2007cites this paper
• Intranasal Delivery of a Thyrotropin‐Releasing Hormone Analog Attenuates Seizures in the Amygdala‐Kindled Rat

  2007cites this paper
• NAP protects hippocampal neurons against multiple toxins.

  2007cites this paper
• NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

  2006cites this paper
• Peptide neuroprotection through specific interaction with brain tubulin

  2006cites this paper
• NAP, a Peptide Derived from the Activity‐Dependent Neuroprotective Protein, Modulates Macrophage Function

  2006cites this paper
• Molecular Chaperones and Cell Signalling: Neuroendocrine Aspects of the Molecular Chaperones ADNF and ADNP

  2005cites this paper
• Neuroprotective peptides as drug candidates against Alzheimer's diasease

  2005cites this paper
• Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.

  2004cites this paper
• Proceedings of the 2003 Summer Neuropeptide Conference, Montauk, New York.

  2004cites this paper